Kala Pharmaceuticals Inc-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Kala Pharmaceuticals Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014089
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:30
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Kala Pharmaceuticals Inc (Kala Pharmaceuticals) is a clinical stage pharmaceutical company which focuses on nanoparticle-based treatments for ocular diseases affecting both front and back of the eye. The company’s lead program MPP nanosuspension of an ophthalmic corticosteroid is under phase III clinical development for the treatment of post-surgical inflammation, ocular inflammation, meibomian gland disease and dry eye disease. Kala Pharmaceuticals is also developing a small molecule receptor tyrosine kinase inhibitor (RTKi) program for the treatment of wet age-related macular degeneration (AMD). The company is funded by life science investors such as Cam Capital, Longitude Capital Management, Lux Capital Management, RA Capital Management, Third Rock Ventures and others. Kala Pharmaceuticals is headquartered in Waltham, Massachusetts, the US.

Kala Pharmaceuticals Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Kala Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Kala Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Kala Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Kala Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Kala Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Kala Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Kala Pharma Raises USD68 Million in Series C Financing Round 10
Kala Pharma Raises USD7 Million in Venture Financing 12
Kala Pharma Raises Us$22.5 Million In Series B Venture Financing 13
Kala Pharma Raises US$11.5 Million In Series A Financing 15
Kala Pharma Raises US$6.2 Million In Seed Financing 17
Equity Offering 18
Kala Pharma Raises USD103.5 Million in IPO 18
Kala Pharmaceuticals Inc – Key Competitors 20
Kala Pharmaceuticals Inc – Key Employees 21
Kala Pharmaceuticals Inc – Locations And Subsidiaries 22
Head Office 22
Recent Developments 23
Financial Announcements 23
Nov 07, 2017: Kala Pharmaceuticals Reports Third Quarter 2017 Financial Results And Provides Business Update 23
Corporate Communications 25
Nov 13, 2017: Kala Pharmaceuticals Appoints Todd Bazemore as Chief Operating Officer 25
Oct 02, 2017: Kala Pharmaceuticals Appoints Andrew I. Koven to Board of Directors 26
Product Approvals 27
Oct 25, 2017: Kala Pharmaceuticals Submits New Drug Application to U.S. Food and Drug Administration for INVELTYS (KPI-121 1%) 27
Clinical Trials 28
May 01, 2017: Kala Pharmaceuticals Announces Positive Results from Confirmatory Phase 3 Trial of KPI-121 1% Following Cataract Surgery 28
Jan 06, 2017: Kala Pharmaceuticals to Present Update on Phase 3 Programs at the 35th Annual J.P. Morgan Healthcare Conference 29
Appendix 30
Methodology 30
About GlobalData 30
Contact Us 30
Disclaimer 30

List of Tables
Kala Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts 2
Kala Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Kala Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Kala Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Kala Pharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Kala Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Kala Pharma Raises USD68 Million in Series C Financing Round 10
Kala Pharma Raises USD7 Million in Venture Financing 12
Kala Pharma Raises Us$22.5 Million In Series B Venture Financing 13
Kala Pharma Raises US$11.5 Million In Series A Financing 15
Kala Pharma Raises US$6.2 Million In Seed Financing 17
Kala Pharma Raises USD103.5 Million in IPO 18
Kala Pharmaceuticals Inc, Key Competitors 20
Kala Pharmaceuticals Inc, Key Employees 21

★海外企業調査レポート[Kala Pharmaceuticals Inc-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Royal FrieslandCampina N.V.:企業のM&A・事業提携・投資動向
    Royal FrieslandCampina N.V. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Royal FrieslandCampina N.V. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acq …
  • Qdoba Restaurant Corporation:企業の戦略・SWOT・財務情報
    Qdoba Restaurant Corporation - Strategy, SWOT and Corporate Finance Report Summary Qdoba Restaurant Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • JSFC Sistema (AFKS):企業の財務・戦略的SWOT分析
    JSFC Sistema (AFKS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Johnson Service Group plc (JSG):企業の財務・戦略的SWOT分析
    Summary Johnson Service Group plc (JSG) is a business and consumer service provider that provides textile services. The company provides dry cleaning and textile rental services. It offers dry cleaning services such as commercial dry cleaning, specialist textile consulting, garment aftercare service …
  • Evolution Petroleum Corp (EPM):石油・ガス:M&Aディール及び事業提携情報
    Summary Evolution Petroleum Corp (EPC), a subsidiary of Esrey Resources Ltd, is an oil and gas company that acquires and explores crude oil and natural gas properties. The company explores for oil, liquefied gas, natural gas, and gas reserves in Delhi field CO2-EOR project. It offers GARP or gas ass …
  • UDG Healthcare Plc (UDG)-医療機器分野:企業M&A・提携分析
    Summary UDG Healthcare plc (UDG) formerly, United Drug plc is a provider of outsourced commercial solutions to healthcare companies. It offers supply chain, packaging, sales and marketing, medical and regulatory services to healthcare manufacturers and pharmaceutical retailers. Its major activities …
  • Vitec Group plc (VTC):企業の財務・戦略的SWOT分析
    Vitec Group plc (VTC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Waterstone Financial Inc (WSBF):企業の財務・戦略的SWOT分析
    Waterstone Financial Inc (WSBF) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Compal Electronics, Inc.:戦略・SWOT・企業財務分析
    Compal Electronics, Inc. - Strategy, SWOT and Corporate Finance Report Summary Compal Electronics, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Volkswagen AG:戦略・SWOT・企業財務分析
    Volkswagen AG - Strategy, SWOT and Corporate Finance Report Summary Volkswagen AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Mayne Pharma Group Ltd (MYX)-製薬・医療分野:企業M&A・提携分析
    Summary Mayne Pharma Group Ltd (Mayne Pharma), formerly Mayne Pharma International Pty Ltd, a subsidiary of Hospira Inc, is a specialty pharmaceutical company that manufactures and markets branded and generic medicinal products. The company’s products comprise astrix capsules and tablets, erymax cap …
  • Sun BioPharma Inc (SNBP):製薬・医療:M&Aディール及び事業提携情報
    Summary Sun BioPharma Inc (Sun BioPharma), formerly Cimarron Medical Inc is a biopharmaceutical company that develops disruptive therapeutics for treatment of pancreatic cancer and pancreatitis. The company’s pipeline products include SBP-101, SBP-102 and SBP-103. Its SBP-101 produces superior anti- …
  • VeriFone Systems Inc:企業の戦略・SWOT・財務分析
    VeriFone Systems Inc - Strategy, SWOT and Corporate Finance Report Summary VeriFone Systems Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Worldpay Us Inc
    Worldpay Us Inc - Strategy, SWOT and Corporate Finance Report Summary Worldpay Us Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Xiwang Special Steel Company Limited:企業の戦略・SWOT・財務情報
    Xiwang Special Steel Company Limited - Strategy, SWOT and Corporate Finance Report Summary Xiwang Special Steel Company Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …
  • Otello Corp ASA (OTELLO):企業の財務・戦略的SWOT分析
    Otello Corp ASA (OTELLO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • BankUnited Inc:企業の戦略・SWOT・財務情報
    BankUnited Inc - Strategy, SWOT and Corporate Finance Report Summary BankUnited Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Selcia Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Selcia Ltd (Selcia), formerly SCYNEXIS Europe Ltd is a contract research company that offers drug discovery services. The company operates through its divisions including selcia discovery - a drug discovery operation, incorporating proprietary fragment screening; and Selcia Radiolabeling - t …
  • Stockland Corporation Ltd:企業のM&A・事業提携・投資動向
    Stockland Corporation Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Stockland Corporation Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisi …
  • Ashmore Group Plc:企業の戦略・SWOT・財務情報
    Ashmore Group Plc - Strategy, SWOT and Corporate Finance Report Summary Ashmore Group Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆